# Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A

> **NCT06961500** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 133 (estimated)

## Conditions studied

- Follicular Lymphoma Grade 3A

## Interventions

- **DRUG:** Obinutuzumab
- **DRUG:** CHOP
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT06961500
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2030-11-01
- **Final completion:** 2030-11-01
- **Target enrollment:** 133 (ESTIMATED)
- **Last updated:** 2025-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06961500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06961500, "Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06961500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*